UNIVERSAL PEACE FEDERATION: World Leaders Renew Call for Peace on the Korean Peninsula During Rally of Hope Showcase of Think Tank 2022
14.9.2021 20:10:00 EEST | Business Wire | Press release
World leaders and experts renewed their calls for peaceful reconciliation on the Korean Peninsula during the virtual Rally of Hope September 12 (KST). The event, broadcasted live from South Korea and attended by millions of online participants from around the world, featured the Universal Peace Federation’s (UPF) new initiative, Think Tank 2022, which seeks to build a global strategy for a major breakthrough for peace by the end of 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005985/en/
Dr. Hak Ja Han Moon addresses the online participants from around the world at the ThinkTank 2022 Rally of Hope (Photo: Business Wire)
“I truly believe that an extraordinary future awaits the people of North Korea — and I have faith that if they pursue the path of denuclearization, they will make that future a magnificent reality,” former U.S. President Donald Trump said in remarks prepared for the event. “Until that blessed day comes, the indispensable force for peace on the Korean Peninsula remains a strong America. As we have seen recently in other parts of the world, weakness only invites more violence and chaos.”
The rally, the seventh such event since August 2020, is among the growing efforts of UPF Co-Founder Dr. Hak Ja Han Moon to address worldwide challenges, including poverty, equality, and environmental degradation, as well as the peaceful reunification of the Korean Peninsula. “Now the time has come for Korea to fulfill its responsibility,” Dr. Moon said at the event. “[T]he prospects for peace on the Korean Peninsula are excellent. This will happen.”
Dr. Moon and her late husband, the Rev. Dr. Sun Myung Moon, are both natives of what is now North Korea and dedicated their lives toward reunifying their homeland and building a more peaceful world. The online rally, which was live-streamed in the U.S. on September 11, included a solemn prayer engaging the global audience in honor of the thousands of lives lost in the 2001 terror attacks.
Other rally speakers included Samdech Hun Sen, prime minister of Cambodia; José Manuel Barroso, former president of the European Commission; Gloria Macapagal Arroyo, former president of The Philippines; H.D. Deve Gowda, former Indian prime minister; Anthony Thomas Aquinas Carmona, former president of Trinidad and Tobago; and Nataša Mićić, former Serbian president.
“As a country placing priceless value upon peace, Cambodia highly appreciates the organization of this rally to strengthen the culture of peace and mutual trust under the framework of international cooperation in the Asia-Pacific area,” said Prime Minister Sen, whose Asian Vision Institute will serve as the Asia-Pacific Secretariat of Think Tank 2022. He recalled when Phnom Penh was captured by the Khmer Rouge in 1975 during the Cambodian Civil War, saying, “We remember the tragedy and are determined to prevent such a similar event from happening again... We vividly understand that peace and nation-building can only be achieved by the local stakeholders in the conflicting country.”
Four governors of South Korean provinces, as well as newly elected Seoul Mayor Oh See-hoon, Gwangju Mayor Lee Yong-sup, and Busan Mayor Park Heong-joon, congratulated Dr. Moon and UPF for the work to advance reconciliation and cooperation on the peninsula. Mr. Barroso, speaking from his longtime experience leading the European Commission, said he strongly supports Korean reunification. “What the global community can do, and I believe it should do even more, is to show strong support to facilitate [and] create the best external conditions for the Koreans themselves to find a way for true reconciliation and peace,” he said.
In her remarks, Mrs. Arroyo said, “With leaders Kim Jong-un and Moon Jae-in exchanging letters since April and announcing the restoration of several communication channels in July — including a military link demolished by the North last year — let Korea’s example teach the world that peace can thrive if humanity can dream together.”
Mr. Carmona said, “Collaborative goodwill is the engine of any successful peace process. Reunification and reconciliation require genuine maturity rather than filibustering, a meeting of the minds and hearts, celebrating the common good — not revisiting the painful past, but rather connecting to the intergenerational and intragenerational hope, ambition, and vision of a united Korean people.”
Think Tank 2022, which is developing Expert Working Groups (EWGs) linked to UPF’s seven international associations, will spearhead peacebuilding projects such as a UN Peace Park on the DMZ, building a Korea-Japan undersea tunnel, boosting Geumgang Mountain tourism development, helping separated Korean families find their relatives, and a call for the UN to establish an office in Korea. Think Tank 2022 has already hosted numerous webinars and will also carry out fact-finding consultations, international leadership conferences, and a major World Summit in South Korea implementing a “One Million People's Relief Association.”
The work of UPF globally aims at promoting constructive dialogue among leaders from all sectors and with diversity of political, philosophical and ideological points of view. In a world characterized too often by polarization and an unwillingness to respectfully engage with those who represent “the other side,” UPF seeks to foster a wider dialogue — a political ecumenism that breaks down barriers and charts a path to mutual respect and understanding. Nowhere is such an approach more desperately needed than that of the Korean Peninsula. For this reason, UPF is engaging with leaders of nations and political parties that are allied with both North and South Korea and are guided by principles of respect, civility, and a commitment to reconciliation.
For additional information about Think Tank 2022 , please click Here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005985/en/
Contact information
EUROPE & THE MIDDLE EAST: Peter Zoehrer
media@europe.upf.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
